Evidence map›Paper›PMID 36612050›Full record

ArticleCancers2022

Influence of Sociodemographic Determinants on the Hodgkin Lymphoma Baseline Characteristics in Long Survivors Patients Enrolled in the Prospective Phase 3 Trial AHL2011.

Steeve Chevreux, Sandra de Barros, Camille Laurent, Amandine Durand, Cyrille Delpierre, Philippine Robert, Clémentine Joubert, Samuel Griolet, Salim Kanoun, Jean-Noël Bastie and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Steeve ChevreuxDepartment of Hematology, Dijon-Bourgogne University Hospital, 21000 Dijon, France.
Sandra de BarrosDepartment of Hematology, University Institute of Cancer Toulouse-Oncopole, 31100 Toulouse, France.
Camille LaurentDepartment of Pathology, University Institute du Cancer, Toulouse University Hospital, 31300 Toulouse, France.
Amandine DurandDepartment of Hematology, Dijon-Bourgogne University Hospital, 21000 Dijon, France.
Cyrille DelpierreDepartment of Hematology, University Institute of Cancer Toulouse-Oncopole, 31100 Toulouse, France.
Philippine RobertDepartment of Hematology, Dijon-Bourgogne University Hospital, 21000 Dijon, France.
Clémentine JoubertLymphoma Academic Research Organisation, CHU Lyon-Sud, 69495 Lyon, France.
Samuel GrioletLymphoma Academic Research Organisation, CHU Lyon-Sud, 69495 Lyon, France.
Salim KanounNuclear Medicine Unit, Institut Universitaire du Cancer Toulouse-Oncopole, 31100 Toulouse, France.ORCID 0000-0002-8592-3773
Jean-Noël BastieDepartment of Hematology, Dijon-Bourgogne University Hospital, 21000 Dijon, France.
René-Olivier CasasnovasDepartment of Hematology, Dijon-Bourgogne University Hospital, 21000 Dijon, France.
Cédric RossiDepartment of Hematology, Dijon-Bourgogne University Hospital, 21000 Dijon, France.
Inserm · FRInstitut universitaire du cancer de Toulouse Oncopole · FRThe Lymphoma Academic Research Organisation · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionWhereas numerous studies on several cancers describe the link between social conditions and disease severity, little is known about the social and demographic characteristics of Hodgkin lymphoma (HL) patients. At diagnosis, 10-15% of the patients in the advanced stages have a well-known poor outcome owing to their chemoresistance, but the determinants of the more advanced stages remain elusive. The objective of the present study was to decipher the potential impact of social disparities on the disease features at diagnosis and analyze how the sociodemographic patient features could impact the HL outcome of patients with advanced-stage HL enrolled in the AHL2011 trial.

methodsThis ancillary study was conducted on a cohort of patients from French centers that had recruited more than five patients in the phase III AHL2011 study (NCT0135874). Patients had to be alive at the time of the ancillary study and had to have given their consent to answer the questionnaire. Pre-treatment data (age, gender, stage, B symptoms, IPS), the treatment received, the responses to PET-CT, and the presence of serious adverse events (serious adverse events-SAEs) were all extracted from the AHL2011 trial database. Sociodemographic data-marital status, living area, level of education, socio-professional category, and professional situation-were extracted from the questionnaires. The population density at the point of diagnosis was determined based on ZIP Code, and the distance from the reference medical center was then calculated by the road network. Baseline PET acquisition was performed before any treatment. PET images at baseline were centrally reviewed. The total metabolic tumor volume (TMTV) at the baseline was calculated using a 41% SUVmax cutoff for each lesion. Progression-free survival was defined as the time from randomization to the first progression, relapse, or death from any cause or the last follow-up. The data cutoff for the analyses presented here was 31 October 2017. The progression-free survival was analyzed on an intention-to-treat basis.

resultsAmong the 823 patients enrolled in the AHL2011 study, the questionnaire was sent to 394 patients, of whom 232 (58.9%) responded. At the time of HL diagnosis, 61.9% (N = 143) of patients declared that they were not socially isolated, 38.1% (N = 88) that they were single, 163 (71.2%) had a professional activity, and 66 (28.8%) were inactive owing to unemployment, retirement, or sick leave. Of the patients, 31.1% (N = 71) lived in a rural region, compared to 68.9% (N = 157) that lived in an urban region. The residence ZIP Code at the time of HL diagnosis was available for 163 (70%). Sociodemographic characteristics did not influence the presence of usual prognostic factors (ECOG, B symptoms, bulky mass, IPS) except for professional activity, which was associated with more frequent low IPS (0-2) (79 (48.5%) active versus 20 (30.3%) inactive patients;

conclusionThis study focused on sociodemographic parameters in advanced-stage HL patients and shows that professional activity is associated with more favorable disease features (low IPS), while patients living in rural or low-populated areas are more likely to have an unfavorable HL presentation with a high tumor burden (high TMTV). These data suggest that some patient sociodemographic characteristics might impact either access to medical care or environmental exposure, leading to a higher frequency of unfavorable presentations. Further prospective sociodemographic studies are necessary to confirm these preliminary results.

Indexed as

Hodgkin lymphomaPETprognosissocial

Identifiers

PMID36612050
PMCPMC9817794
OpenAlexW4312172225

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.